Non Alcoholic Fatty Liver Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Non Alcoholic Fatty Liver Disease stocks.

Non Alcoholic Fatty Liver Disease Stocks Recent News

Date Stock Title
May 10 GYRE Gyre Therapeutics GAAP EPS of $0.03, revenue of $27.17M
May 9 GYRE Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 9 VKTX Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired
May 8 TERN Terns Pharmaceuticals Announces Leadership Changes
May 8 BLTE Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
May 8 PLRX Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)
May 7 TERN Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
May 7 SGMT Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
May 7 PLRX Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
May 6 PLRX Pliant Therapeutics GAAP EPS of -$0.78 misses by $0.01
May 6 PLRX Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 6 VKTX Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 72% of the company
May 6 BLTE Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
May 6 SGMT Sagimet Biosciences gets new finance head
May 6 BLTE Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
May 6 SGMT Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
Non Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver, causing inflammation and damage. It is the most common form of liver disease in the United States, affecting up to 25% of the population. NAFLD is closely linked to obesity, diabetes, and high cholesterol, and can lead to serious complications such as cirrhosis and liver cancer. Treatment typically involves lifestyle changes such as weight loss, exercise, and a healthy diet.

Browse All Tags